Employees: 2,169
Size Viva Biotech (1873.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $303M, the 882nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$1.17 on 18 Nov 2026.
Performance Over six months the shares fell 18.2%, against -31.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 7.4% over the last twelve months (peer median +5.7%); the operating margin is 9.9% (peer median -244.5%).
Valuation It trades at 8.1× forward earnings.
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.7 points below its cost of capital (11.7% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$2.13B | HK$1.88B | HK$2.15B | HK$2.38B | HK$2.77B |
| Revenue growth | — | -13% | -10% | -14% | — |
| Gross profit | HK$736M | HK$711M | HK$745M | HK$816M | HK$949M |
| EBITDA | HK$440M | HK$438M | HK$481M | HK$446M | HK$525M |
| Net income | HK$199M | HK$238M | HK$181M | -HK$128M | -HK$615M |
| Free cash flow | HK$323M | HK$98.0M | HK$162M | HK$187M | HK$80.4M |
| Capital expenditure | HK$168M | HK$133M | HK$208M | HK$193M | HK$271M |
| Total debt | n/a | HK$1.48B | HK$1.37B | HK$2.10B | HK$3.17B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1873.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.6% | -4.7% | 6th lowest of 20 |
| 6-month return | -18.2% | -31.0% | 6th highest of 20 |
| Distance from 52-week high | -59.1% | -52.1% | 8th lowest of 20 |
| Revenue growth (TTM) | +7.4% | +5.7% | 6th highest of 13 |
| Operating margin | 9.9% | -244.5% | 4th highest of 15 |
| Forward P/E | 8.1× | n/a | — |
| Growth the price implies (Req g, 7 yrs) | 2.6% | n/a | — |
| Growth delivered (Del g) | +19.1% | n/a | — |
| Hurdle (Req g minus delivered) | -16.5 pp | n/a | — |
| ROIC minus cost of capital | -7.7 pp | -63.8 pp | 5th highest of 14 |
| EV / EBITDA | 5.0× | 12.4× | 2nd cheapest of 6 |
| Net debt / EBITDA | -0.4× | -3.5× | 2nd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Viva Biotech 1873.HK | Hong Kong | $303M | -18% | +7% | 10% | 8.1× | 2.6% | +19.1% |
| X4 Pharmaceuticals XFOR | United States | $304M | -21% | -50% | -474% | n/a | n/a | n/a |
| Greenwich LifeSciences GLSI | United States | $302M | -25% | n/a | n/a | n/a | n/a | n/a |
| Galectin Therapeutics GALT | United States | $301M | +35% | n/a | n/a | n/a | n/a | n/a |
| Cuorips 4894.T | Japan | $309M | -10% | -80% | -1,765% | n/a | n/a | n/a |
| Nautilus Biotechnolgy NAUT | United States | $310M | +2% | n/a | -15,106% | n/a | n/a | n/a |
| ProKidney PROK | United States | $314M | -38% | +4% | -24,830% | n/a | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $319M | -79% | +395% | -173% | n/a | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $321M | -31% | n/a | n/a | n/a | n/a | n/a |
| C4 Therapeutics CCCC | United States | $325M | -25% | +7% | -316% | n/a | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $326M | -53% | n/a | -57% | n/a | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $331M | -17% | +14% | 36% | 10.5× | n/a | n/a |
| Larimar Therapeutics LRMR | United States | $337M | -9% | n/a | n/a | n/a | n/a | n/a |
| GI Innovation 358570.KS | South Korea | $339M | -47% | +1,527% | -918% | n/a | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $341M | -19% | -63% | -1,388,360% | n/a | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $349M | n/a | n/a | n/a | n/a | n/a | n/a |
| Medy-Tox 086900.KS | South Korea | $350M | -36% | +3% | 10% | 18.1× | 4.7% | +11.9% |
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | n/a | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | n/a | 0.6% | +725.2% |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | n/a | n/a | n/a |